An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis

Temporomandibular joint osteoarthritis (TMJOA) is a degenerative disease characterized by cartilage degeneration, disrupted subchondral bone remodeling, and synovitis, seriously affecting the quality of life of patients with chronic pain and functional disabilities. Current treatments for TMJOA are...

Full description

Saved in:
Bibliographic Details
Main Authors: Yifan Zhao, Liang Xie
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2021/6619527
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850174697179709440
author Yifan Zhao
Liang Xie
author_facet Yifan Zhao
Liang Xie
author_sort Yifan Zhao
collection DOAJ
description Temporomandibular joint osteoarthritis (TMJOA) is a degenerative disease characterized by cartilage degeneration, disrupted subchondral bone remodeling, and synovitis, seriously affecting the quality of life of patients with chronic pain and functional disabilities. Current treatments for TMJOA are mainly symptomatic therapies without reliable long-term efficacy, due to the limited self-renewal capability of the condyle and the poorly elucidated pathogenesis of TMJOA. Recently, there has been increased interest in cellular therapies for osteoarthritis and TMJ regeneration. Mesenchymal stem cells (MSCs), self-renewing and multipotent progenitor cells, play a promising role in TMJOA treatment. Derived from a variety of tissues, MSCs exert therapeutic effects through diverse mechanisms, including chondrogenic differentiation; fibrocartilage regeneration; and trophic, immunomodulatory, and anti-inflammatory effects. Here, we provide an overview of the therapeutic roles of various tissue-specific MSCs in osteoarthritic TMJ or TMJ regenerative tissue engineering, with an additional focus on joint-resident stem cells and other cellular therapies, such as exosomes and adipose-derived stromal vascular fraction (SVF). Additionally, we summarized the updated pathogenesis of TMJOA to provide a better understanding of the pathological mechanisms of cellular therapies. Although limitations exist, MSC-centered therapies still provide novel, innovative approaches for TMJOA treatment.
format Article
id doaj-art-ca426c38fd974dbf8af03be3ddb40302
institution OA Journals
issn 1687-966X
1687-9678
language English
publishDate 2021-01-01
publisher Wiley
record_format Article
series Stem Cells International
spelling doaj-art-ca426c38fd974dbf8af03be3ddb403022025-08-20T02:19:37ZengWileyStem Cells International1687-966X1687-96782021-01-01202110.1155/2021/66195276619527An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint OsteoarthritisYifan Zhao0Liang Xie1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, ChinaState Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, ChinaTemporomandibular joint osteoarthritis (TMJOA) is a degenerative disease characterized by cartilage degeneration, disrupted subchondral bone remodeling, and synovitis, seriously affecting the quality of life of patients with chronic pain and functional disabilities. Current treatments for TMJOA are mainly symptomatic therapies without reliable long-term efficacy, due to the limited self-renewal capability of the condyle and the poorly elucidated pathogenesis of TMJOA. Recently, there has been increased interest in cellular therapies for osteoarthritis and TMJ regeneration. Mesenchymal stem cells (MSCs), self-renewing and multipotent progenitor cells, play a promising role in TMJOA treatment. Derived from a variety of tissues, MSCs exert therapeutic effects through diverse mechanisms, including chondrogenic differentiation; fibrocartilage regeneration; and trophic, immunomodulatory, and anti-inflammatory effects. Here, we provide an overview of the therapeutic roles of various tissue-specific MSCs in osteoarthritic TMJ or TMJ regenerative tissue engineering, with an additional focus on joint-resident stem cells and other cellular therapies, such as exosomes and adipose-derived stromal vascular fraction (SVF). Additionally, we summarized the updated pathogenesis of TMJOA to provide a better understanding of the pathological mechanisms of cellular therapies. Although limitations exist, MSC-centered therapies still provide novel, innovative approaches for TMJOA treatment.http://dx.doi.org/10.1155/2021/6619527
spellingShingle Yifan Zhao
Liang Xie
An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis
Stem Cells International
title An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis
title_full An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis
title_fullStr An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis
title_full_unstemmed An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis
title_short An Update on Mesenchymal Stem Cell-Centered Therapies in Temporomandibular Joint Osteoarthritis
title_sort update on mesenchymal stem cell centered therapies in temporomandibular joint osteoarthritis
url http://dx.doi.org/10.1155/2021/6619527
work_keys_str_mv AT yifanzhao anupdateonmesenchymalstemcellcenteredtherapiesintemporomandibularjointosteoarthritis
AT liangxie anupdateonmesenchymalstemcellcenteredtherapiesintemporomandibularjointosteoarthritis
AT yifanzhao updateonmesenchymalstemcellcenteredtherapiesintemporomandibularjointosteoarthritis
AT liangxie updateonmesenchymalstemcellcenteredtherapiesintemporomandibularjointosteoarthritis